Orio Therapeutics modifies therapeutic proteins with a patented technology that embeds a built-in delivery system to keep molecules at the targeted injection site, addressing poor localization in protein therapeutics. Its lead program is a cardioprotective drug for post–myocardial infarction care designed to limit inflammation, improve survival and quality of life, and speed recovery. The company plans to use the CHF 150,000 from Venture Kick to fund preclinical development, including a crucial efficacy study scheduled for late 2024. The technology was developed at Monash University's Australian Regenerative Medicine Institute and the company was incorporated at the BioArk Technological Site in Monthey in early 2023. The founding team comprises EPFL alumni CEO Ziad Julier and CSO Mikaël Martino. The company targets a myocardial infarction market currently exceeding USD 20 billion. Orio Therapeutics applies protein engineering and targeted drug delivery to create next-generation regenerative medicines. Its lead program is a cardioprotective drug designed to prevent extensive, often irreversible damage following acute myocardial infarction. The company announced a CHF 500,000 pre-seed funding round that will be used to initiate crucial pre-clinical studies for the lead program. Orio's platform aims to address fundamental limitations in current treatments, promising increased effectiveness and reduced side effects across multiple therapeutic areas. The company is headquartered at the BioArk Technological Site in Monthey, Valais, Switzerland, and maintains a secondary location at Monash University in Melbourne, Australia. Dr. Ziad Julier is the company's CEO.

Total raised

$1M

Funding rounds

2

Latest round

Seed

Latest activity

Jun 2024